不同剂量异甘草酸镁对肝功能异常的慢性乙肝患者症状疗效及肝功能的影响

摘要

Objective To study the influences of different dosages of magnesium isogly-cyrrhizinate on symptomatic effects and liver function of chronic hepatitis B (CHB) patients with liver dysfunction. Methods According to randomized controlled method, 200 CHB patients combined with liver dysfunction were divided into 5 groups, namely groups A, B, C, D and E, with 40 cases in each group. All patients were respectively administered 100, 150, 200, 250 and 300 mg of magnesium isoglycyrrhizinate. The improved conditions of clinical symptoms and each index change of liver function of patients before and after treatment were observed. Results After treatment, the number of each symptom, alamine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBiL) of all patients significantly decreased compared with previous treatment. The number of each symptom, ALT, AST and TBiL of patients in 4 groups with over 150 mg after treatment were all lower than that of group A, and there was no statistical significance among those 4 groups. Severe adverse reactions were not observed in patients before and after treatment. Conclusion 150mg of magnesium isoglycyrrhizinate, conspicuously capable of ameliorating the clinical effects of CHB patients with liver dysfunction and decreasing each index level of liver function immediately, is the optimized clinical dosage.%目的 研究不同剂量异甘草酸镁对肝功能异常的慢性乙肝患者的症状疗效及肝功能的影响.方法 将200例合并肝功能异常的慢性乙肝患者按照随机对照法分为A、B、C、D、E共5组,每组40例,分别给予100、150、200、250及300 mg异甘草酸镁治疗,观察所有患者治疗前后临床症状改善情况及肝功能各指标变化.结果 所有患者治疗后各症状所占病例数、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)及总胆红素(TBiL)均较治疗前显著下降,150 mg以上4组患者治疗后各症状病例数、ALT、AST及TBiL均显著低于A组,且4组之间差异无统计学意义.患者治疗前后均未发现严重不良反应.结论 150mg异甘草酸镁即可明显改善肝功能异常的慢性乙肝患者临床症状,降低肝功能各指标水平,是临床治疗的首选剂量.